Biotech-Focused Longitude Capital Closes $525M Fund
Private equity firm Longitude Capital said Tuesday that it has closed its third fund with $525 million, which it will look to invest in biotechnology and medical technology companies across all...To view the full article, register now.
Already a subscriber? Click here to view full article